[go: up one dir, main page]

WO2021091434A3 - Structure de génie génétique pour stimuler l'angiogenèse - Google Patents

Structure de génie génétique pour stimuler l'angiogenèse Download PDF

Info

Publication number
WO2021091434A3
WO2021091434A3 PCT/RU2021/050002 RU2021050002W WO2021091434A3 WO 2021091434 A3 WO2021091434 A3 WO 2021091434A3 RU 2021050002 W RU2021050002 W RU 2021050002W WO 2021091434 A3 WO2021091434 A3 WO 2021091434A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene
genetic engineering
angiogenesis
blood supply
growth factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/RU2021/050002
Other languages
English (en)
Russian (ru)
Other versions
WO2021091434A8 (fr
WO2021091434A2 (fr
WO2021091434A9 (fr
Inventor
Екатерина Александровна СЛОБОДКИНА
Максим Николаевич КАРАГЯУР
Вадим Юрьевич Балабаньян
Елена Викторовна ПАРФЕНОВА
Павел Игоревич МАКАРЕВИЧ
Жанна Алексеевна АКОПЯН
Всеволод Арсеньевич ТКАЧУК
Мария Александровна БОЛДЫРЕВА
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
<<gene And Cell Therapy>> LLC
Original Assignee
<<gene And Cell Therapy>> LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by <<gene And Cell Therapy>> LLC filed Critical <<gene And Cell Therapy>> LLC
Publication of WO2021091434A2 publication Critical patent/WO2021091434A2/fr
Publication of WO2021091434A8 publication Critical patent/WO2021091434A8/fr
Publication of WO2021091434A9 publication Critical patent/WO2021091434A9/fr
Publication of WO2021091434A3 publication Critical patent/WO2021091434A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention se rapporte au domaine des biotechnologies, concerne plus précisément des structures de génie génétique pour stimuler l'angiogenèse, et peut être utilisée en médecine afin de traiter des maladies liées à un trouble de l'apport en sang des tissus. L'invention concerne une structure bicistronique plasmide porteuse du gène hHGF de facteur de croissance d'hépatites humain et du gène hVEGF165 de facteur de croissance endothéliale des vaisseaux avec deux promoteurs distincts pour chacun des gènes: promoteur de citomégalovirus pCMV pour le gène HGF et promoteur de gène de β-actine du poussin pCAG pour le gène VEGF165. Cette structure bicistronique peut être utilisée en qualité d'agent médicamenteux afin d'assurer la stimulation de l'angiogenèse, la croissance et le remodelage de vaisseaux, ainsi que la restauration de l'alimentation en sang dans des tissus ischémiques. Cette invention permet d'atteindre des concentrations optimales et une corrélation des facteurs angiogènes de croissance (FAC).
PCT/RU2021/050002 2019-11-06 2021-01-05 Structure de génie génétique pour stimuler l'angiogenèse Ceased WO2021091434A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2019135603A RU2737487C1 (ru) 2019-11-06 2019-11-06 Генно-инженерная конструкция для стимуляции ангиогенеза
RU2019135603 2019-11-06

Publications (4)

Publication Number Publication Date
WO2021091434A2 WO2021091434A2 (fr) 2021-05-14
WO2021091434A8 WO2021091434A8 (fr) 2021-06-10
WO2021091434A9 WO2021091434A9 (fr) 2021-07-08
WO2021091434A3 true WO2021091434A3 (fr) 2021-09-23

Family

ID=73792491

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2021/050002 Ceased WO2021091434A2 (fr) 2019-11-06 2021-01-05 Structure de génie génétique pour stimuler l'angiogenèse

Country Status (2)

Country Link
RU (1) RU2737487C1 (fr)
WO (1) WO2021091434A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022176A1 (fr) * 2000-09-15 2002-03-21 Genvec, Inc. Procede de modulation de neovascularisation
CN102242148A (zh) * 2010-10-09 2011-11-16 苏州大学 重组载体以及转基因骨髓基质细胞修饰的丝素膜及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1204247C (zh) * 2001-06-15 2005-06-01 中国人民解放军军事医学科学院百环生物医学研究中心 一种重组腺病毒及其在心肌缺血治疗中的应用
RU2449799C2 (ru) * 2009-10-30 2012-05-10 Федеральное Государственное Учреждение "Российский кардиологический научно-производственный комплекс Федерального агентства по высокотехнологичной медицинской помощи" Средство для осуществления терапевтического ангиогенеза и способ его осуществления

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022176A1 (fr) * 2000-09-15 2002-03-21 Genvec, Inc. Procede de modulation de neovascularisation
CN102242148A (zh) * 2010-10-09 2011-11-16 苏州大学 重组载体以及转基因骨髓基质细胞修饰的丝素膜及其应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MAKAREVICH PAVEL ET AL: "Combined Transfer of Human VEGF165 and HGF Genes Renders Potent Angiogenic Effect in Ischemic Skeletal Muscle", PLOS ONE, vol. 7, no. 6, 13 June 2012 (2012-06-13), pages e38776, XP055826391, DOI: 10.1371/journal.pone.0038776 *
SLOBODKINA E A: "Development of a plasmid construct encoding HGF and VEGF165 for gene therapy.", EUROPEAN SOCIETY OF GENE & CELL THERAPY GENE AND CELL THERAPY (SFTCG) LAUSANNE, P469, 1 December 2018 (2018-12-01), pages 1 - 169, XP055826478, Retrieved from the Internet <URL:https://www.liebertpub.com/doi/pdfplus/10.1089/hum.2018.29077.abstracts> [retrieved on 20210721] *
YOON C S ET AL: "Sonoporation of the Minicircle-VEGF165 for Wound Healing of Diabetic Mice", PHARMACEUTICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NL, vol. 26, no. 4, 8 November 2008 (2008-11-08), pages 794 - 801, XP019686117, ISSN: 1573-904X *

Also Published As

Publication number Publication date
WO2021091434A8 (fr) 2021-06-10
WO2021091434A2 (fr) 2021-05-14
WO2021091434A9 (fr) 2021-07-08
RU2737487C1 (ru) 2020-12-01

Similar Documents

Publication Publication Date Title
Van Weel et al. Vascular growth in ischemic limbs: a review of mechanisms and possible therapeutic stimulation
Markkanen et al. Growth factor-induced therapeutic angiogenesis and arteriogenesis in the heart–gene therapy
Mao et al. Potential suppression of the high glucose and insulin-induced retinal neovascularization by Sirtuin 3 in the human retinal endothelial cells
Bunch et al. Novel therapeutics for diabetic retinopathy and diabetic macular edema: a pathophysiologic perspective
Bikfalvi Angiogenesis: health and disease
CN101319229B (zh) 重组人bFGF和人PDGF-B的双基因腺病毒载体及其用途
WO2021091434A8 (fr) Structure de génie génétique pour stimuler l&#39;angiogenèse
JP2024503725A (ja) 小分子調節遺伝子発現システム
EA031883B1 (ru) Способ ингибирования и/или снижения образования рубцовой ткани
US7709450B2 (en) Stimulation of vascularization with VEGF-B-186
Zacchigna et al. Gene therapy perspectives for nerve repair
Lebas et al. Therapeutic benefits and adverse effects of combined proangiogenic gene therapy in mouse critical leg ischemia
Hosseinpour et al. Impact of photobiomodulation using four diode laser wavelengths of on cationic liposome gene transfection into pre-osteoblast cells
Watkins et al. HB-EGF augments the ability of mesenchymal stem cells to attenuate intestinal injury
MX2024013830A (es) Construccion de acido nucleico que comprende utr y uso de la misma
Xu et al. Cardiac-specific expression of the hepatocyte growth factor (HGF) under the control of a TnIc promoter confers a heart protective effect after myocardial infarction (MI)
RU2449799C2 (ru) Средство для осуществления терапевтического ангиогенеза и способ его осуществления
Picichè et al. Enhancement of noncoronary collateral circulation: the hypothesis of an alternative treatment for ischemic heart disease
Donati et al. Angiogenesis and the progress of vascular and tumor biology: a tribute to Judah Folkman
US20050090464A1 (en) Vectors for enhanced expression of Vegf for disease treatment
CA2561978A1 (fr) Molecules therapeutiques pour moduler la stabilite de transcrits du vegf
Nuutila et al. Gene therapy in skin and wound healing
CN114042079B (zh) Rna在治疗扩张性心肌病和心肌纤维化中的应用
RU2628706C2 (ru) Способ стимуляции ангиогенеза в ишеминизированных тканях и комбинированное лекарственное средство для осуществления способа
Mcmahon et al. 6 Molecular Approaches to Revascularization in Peripheral Vascular Disease

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 26/09/2022)

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21714281

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 21714281

Country of ref document: EP

Kind code of ref document: A2